The study investigated the influence of basic physical factors induced by magnetite nanoparticles (constant magnetic field and sorption) on microorganisms by examining the intensity of free radical lipid peroxidation (FRLP) and bacteriostatic action. It was established that magnetite nanoparticles (MCS-B) elicited varying FRLP intensity reactions across different microorganism groups. The constant magnetic field induced by nanoparticles was identified as the most significant factor affecting the luminescence intensity in Candida albicans, Escherichia coli, and Pseudomonas aeruginosa. Conversely, sorption was the most significant factor for Staphylococcus aureus. The study found that the rate of free radical lipid consumption decreased significantly in all microorganisms after treatment with magnetite nanoparticles (MCS-B). Microbiological analysis of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus demonstrated a bacteriostatic effect following exposure to magnetite nanoparticles, evidenced by a reduction in colony numbers on the nutrient medium compared to the control (Fig. 1). An intriguing finding was that saline NaCl, pre-treated with magnetite nanoparticles, also exhibited a significant bacteriostatic effect on the studied microorganisms. This effect is likely due to changes in the polarization structure of the microorganisms' water induced by the magnetite nanoparticles. It was discovered that the degree of bacteriostatic action induced by magnetite nanoparticles correlated with the intensity of FRLP reactions. The maximum bacteriostatic effect on Staphylococcus aureus was observed in the second variant of nanoparticle application, where the sorption mechanism was more significant than the magnetic field's effect. Conversely, the maximum bacteriostatic effect on Escherichia coli and Klebsiella pneumoniae was observed in the third variant, where the duration of nanoparticle contact with the microorganisms, and consequently the action of the constant magnetic field, was the determining factor.

Andrey N. Belousov, PhD, DM, Professor, is a Ukrainian medical scientist and pioneer in nanotechnology, who developed the world’s first biocompatible nanomedical drugs “Micromage-B,” “MCS-B”, and “ICNB,” introduced into clinical practice in 1998. His work established a translational model linking fundamental biophysics with clinical medicine, with applications in detoxification, hemocorrection, and tissue protection. He has authored more than 370 scientific publications, holds 9 patents, and leads the Laboratory of Applied Nanotechnologies at Kharkiv National Medical University, Ukraine. His research focuses on nanomedicine, critical care pharmacology, blood rheology correction, and the clinical application of nanostructured materials in personalized and minimally invasive therapies.